Increased prevalence of diabetes mellitus and the metabolic syndrome in patients with primary aldosteronism of the German Conn's Registry

European Journal of Endocrinology

Volumn 173, Issue 5, 2015, Pages 665-675

  Hanslik, Gregor ^a   Wallaschofski, Henri ^b   Dietz, Anna ^c   Riester, Anna ^c   Reincke, Martin ^c   Allolio, Bruno ^d   Lang, Katharina ^d   Quack, Ivo ^e   Rump, Lars C ^e   Willenberg, Holger S ^f   Beuschlein, Felix ^c   Quinkler, Marcus ^a,g   Hannemann, Anke ^b  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b UNIVERSITY MEDICINE GREIFSWALD   (Germany)

^c LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^d UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

^e Department of Orthopedic Surgery   (Germany)

^f ROSTOCK UNIVERSITY MEDICAL CENTER   (Germany)

^g Endocrinology in Charlottenburg   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

HEMOGLOBIN A1C; MINERALOCORTICOID ANTAGONIST; POTASSIUM;

ADRENALECTOMY; ADULT; ARTICLE; CONTROLLED STUDY; FEMALE; FOLLOW UP; GERMANY; HUMAN; IMPAIRED GLUCOSE TOLERANCE; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; MIDDLE AGED; NON INSULIN DEPENDENT DIABETES MELLITUS; ORAL GLUCOSE TOLERANCE TEST; POTASSIUM BLOOD LEVEL; PREVALENCE; PRIMARY HYPERALDOSTERONISM; PRIORITY JOURNAL; COMORBIDITY; DIABETES MELLITUS, TYPE 2; HYPERALDOSTERONISM; PROSPECTIVE STUDY; REGISTER; STATISTICS AND NUMERICAL DATA; TRENDS;

ADULT; COMORBIDITY; DIABETES MELLITUS, TYPE 2; FEMALE; GERMANY; HUMANS; HYPERALDOSTERONISM; MALE; METABOLIC SYNDROME X; MIDDLE AGED; PREVALENCE; PROSPECTIVE STUDIES; REGISTRIES;

EID: 84946068687     PISSN: 08044643     EISSN: 1479683X     Source Type: Journal    
DOI: 10.1530/EJE-15-0450     Document Type: Article

References (52)

1. Hannemann A & Wallaschofski H. Prevalence of primary aldosteronism in patient's cohorts and in population-based studies-a review of the current literature. Hormone and Metabolic Research 2012 44 157-162. (doi:10.1055/s-0031-1295438)
2. Born-Frontsberg E, Reincke M, Rump LC, Hahner S, Diederich S, Lorenz R, Allolio B, Seufert J, Schirpenbach C, Beuschlein F et al. Cardiovascular and cerebrovascular comorbidities of hypokalemic and normokalemic primary aldosteronism: results of the German Conn's Registry. Journal of Clinical Endocrinology and Metabolism 2009 94 1125-1130. (doi:10.1210/jc.2008-2116)
3. Milliez P, Girerd X, Plouin PF, Blacher J, Safar ME & Mourad JJ. Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism. Journal of the American College of Cardiology 2005 45 1243-1248. (doi:10.1016/j.jacc.2005.01.015)
4. Brown NJ. Contribution of aldosterone to cardiovascular and renal inflammation and fibrosis. Nature Reviews. Nephrology 2013 9 459-469. (doi:10.1038/nrneph.2013.110)
5. Korte S, Strater AS, Druppel V, Oberleithner H, Jeggle P, Grossmann C, Fobker M, Nofer JR, Brand E & Kusche-Vihrog K. Feedforward activation of endothelial ENaC by high sodium. FASEB Journal 2014 28 4015-4025. (doi:10.1096/fj.14-250282)
6. Van Gaal LF, Mertens IL & De Block CE. Mechanisms linking obesity with cardiovascular disease. Nature 2006 444 875-880. (doi:10.1038/nature05487)
7. Pitt B, Remme W, Zannad F, Neaton J, Martinez F, Roniker B, Bittman R, Hurley S, Kleiman J & Gatlin M. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. New England Journal of Medicine 2003 348 1309-1321. (doi:10.1056/NEJMoa030207)
8. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, Palensky J & Wittes J. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. New England Journal of Medicine 1999 341 709-717. (doi:10.1056/NEJM199909023411001)
9. Hao G, Wang Z, Guo R, Chen Z, Wang X, Zhang L & Li W. Effects of ACEI/ARB in hypertensive patients with type 2 diabetes mellitus: a meta-analysis of randomized controlled studies. BMC Cardiovascular Disorders 2014 14 148. (doi:10.1186/1471-2261-14-148)
10. Al-Mallah M, Khawaja O, Sinno M, Alzohaili O & Samra AB. Do angiotensin converting enzyme inhibitors or angiotensin receptor blockers prevent diabetes mellitus? A meta-analysis Cardiology Journal 2010 17 448-456.
11. Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care 2003 26 (Suppl 1) S5-S20.
12. Ishimori M, Takeda N, Okumura S, Murai T, Inouye H & Yasuda K. Increased insulin sensitivity in patients with aldosterone producing adenoma. Clinical Endocrinology 1994 41 433-438. (doi:10.1111/j.1365-2265.1994.tb02573.x)
13. Sindelka G, Widimsky J, Haas T, Prazny M, Hilgertova J & Skrha J. Insulin action in primary hyperaldosteronism before and after surgical or pharmacological treatment. Experimental and Clinical Endocrinology & Diabetes 2000 108 21-25.
14. Strauch B, Widimsky J, Sindelka G & Skrha J. Does the treatment of primary hyperaldosteronism influence glucose tolerance? Physiological Research 2003 52 503-506.
15. Skrha J, Haas T, Sindelka G, Prazny M, Widimsky J, Cibula D & Svacina S. Comparison of the insulin action parameters from hyperinsulinemic clamps with homeostasis model assessment and QUICKI indexes in subjects with different endocrine disorders. Journal of Clinical Endocrinology and Metabolism 2004 89 135-141. (doi:10.1210/jc.2002-030024)
16. Fallo F, Veglio F, Bertello C, Sonino N, Della Mea P, Ermani M, Rabbia F, Federspil G & Mulatero P. Prevalence and characteristics of the metabolic syndrome in primary aldosteronism. Journal of Clinical Endocrinology and Metabolism 2006 91 454-459. (doi:10.1210/jc.2005-1733)
17. Sasaki N, Iwase M, Arima H, Nohara S, Bandai S, Yao T, Fujii K & Iida M. Overt diabetes mellitus in a patient with combined primary aldoster-onism and Cushing's syndrome. Internal Medicine 2006 45 1237-1242. (doi:10.2169/internalmedicine.45.1855)
18. Catena C, Lapenna R, Baroselli S, Nadalini E, Colussi G, Novello M, Favret G, Melis A, Cavarape A & Sechi LA. Insulin sensitivity in patients with primary aldosteronism: a follow-up study. Journal of Clinical Endocrinology and Metabolism 2006 91 3457-3463. (doi:10.1210/jc. 2006-0736)
19. Mosso LM, Carvajal CA, Maiz A, Ortiz EH, Castillo CR, Artigas RA & Fardella CE. A possible association between primary aldosteronism and a lower b-cell function. Journal of Hypertension 2007 25 2125-2130. (doi:10.1097/HJH.0b013e3282861fa4)
20. Colussi G, Catena C, Lapenna R, Nadalini E, Chiuch A & Sechi LA. Insulin resistance and hyperinsulinemia are related to plasma aldosterone levels in hypertensive patients. Diabetes Care 2007 30 2349-2354. (doi:10.2337/dc07-0525)
21. Matrozova J, Steichen O, Amar L, Zacharieva S, Jeunemaitre X & Plouin PF. Fasting plasma glucose and serum lipids in patients with primary aldosteronism: a controlled cross-sectional study. Hypertension 2009 53 605-610. (doi:10.1161/HYPERTENSIONAHA.108.122002)
22. Giacchetti G, Sechi LA, Rilli S & Carey RM. The renin-angiotensin-aldosterone system, glucose metabolism and diabetes. Trends in Endocrinology and Metabolism 2005 16 120-126. (doi:10.1016/j.tem. 2005.02.003)
23. Sowers JR, Whaley-Connell A & Epstein M. Narrative review: The emerging clinical implications of the role of aldosterone in the metabolic syndrome and resistant hypertension. Annals of Internal Medicine 2009 150 776-783. (doi:10.7326/0003-4819-150-11-200906020-00005)
24. Cooper SA, Whaley-Connell A, Habibi J, Wei Y, Lastra G, Manrique C, Stas S & Sowers JR. Renin-angiotensin-aldosterone system and oxidative stress in cardiovascular insulin resistance. American Journal of Physiology. Heart and Circulatory Physiology 2007 293 H2009-H2023. (doi:10.1152/ajpheart.00522.2007)
25. Reincke M, Meisinger C, Holle R, Quinkler M, Hahner S, Beuschlein F, Bidlingmaier M, Seissler J & Endres S. Is primary aldosteronism associated with diabetes mellitus? Results of the German Conn's Registry Hormone and Metabolic Research 2010 42 435-439. (doi:10.1055/s-0029-1246189)
26. Schipf S, Werner A, Tamayo T, Holle R, Schunk M, Maier W, Meisinger C, Thorand B, Berger K, Mueller G et al. Regional differences in the prevalence of known type 2 diabetes mellitus in 45-74 years old individuals: results from six population-based studies in Germany (DIAB-CORE Consortium). Diabetic Medicine 2012 29 e88-e95. (doi:10.1111/j.1464-5491.2012.03578.x)
27. Schirpenbach C, Segmiller F, Diederich S, Hahner S, Lorenz R, Rump LC, Seufert J, Quinkler M, Bidlingmaier M, Beuschlein F et al. The diagnosis and treatment of primary hyperaldosteronism in Germany: results on 555 patients from the German Conn Registry. Deutsches Ärzteblatt International 2009 106 305-311. (doi:10.3238/arztebl.2009. 0305)
28. Funder JW, Carey RM, Fardella C, Gomez-Sanchez CE, Mantero F, Stowasser M, Young WF Jr & Montori VM. Case detection, diagnosis, and treatment of patients with primary aldosteronism: an Endocrine Society clinical practice guideline. Journal of Clinical Endocrinology and Metabolism 2008 93 3266-3281. (doi:10.1210/jc.2008-0104)
29. Mulatero P, Dluhy RG, Giacchetti G, Boscaro M, Veglio F & Stewart PM. Diagnosis of primary aldosteronism: from screening to subtype differentiation. Trends in Endocrinology and Metabolism 2005 16 114-119. (doi:10.1016/j.tem.2005.02.007)
30. Riester A, Fischer E, Degenhart C, Reiser MF, Bidlingmaier M, Beuschlein F, Reincke M & Quinkler M. Age below 40 or a recently proposed clinical prediction score cannot bypass adrenal venous sampling in primary aldosteronism. Journal of Clinical Endocrinology and Metabolism 2014 99 E1035-E1039. (doi:10.1210/jc.2013-3789)
31. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care 2012 35 (Suppl 1) S64-S71.
32. Volzke H, Alte D, Schmidt CO, Radke D, Lorbeer R, Friedrich N, Aumann N, Lau K, Piontek M, Born G et al. Cohort profile: The Study of Health In Pomerania. International Journal of Epidemiology 2011 40 294-307. (doi:10.1093/ije/dyp394)
33. John U, Greiner B, Hensel E, Ludemann J, Piek M, Sauer S, Adam C, Born G, Alte D, Greiser E et al. Study of Health In Pomerania (SHIP): a health examination survey in an east German region: objectives and design. Sozial-und Präventivmedizin 2001 46 186-194.
34. Hannemann A, Friedrich N, Ludemann J, Volzke H, Rettig R, Peters J, Reincke M, Doring A, Nauck M & Wallaschofski H. Reference intervals for aldosterone, renin, and the aldosterone-to-renin ratio in the population-based Study of Health In Pomerania (SHIP-1). Hormone and Metabolic Research 2010 42 392-399. (doi:10.1055/s-0030-1247545)
35. Alberti KG, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, Donato KA, Fruchart JC, James WP, Loria CM & Smith SC Jr. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 2009 120 1640-1645. (doi:10.1161/CIRCULATIONAHA.109.192644)
36. Luders S, Hammersen F, Kulschewski A, Venneklaas U, Zuchner C, Gansz A, Schnieders M, Pfarr E, Sturm CD, Paar WD et al. Diagnosis of impaired glucose tolerance in hypertensive patients in daily clinical practice. International Journal of Clinical Practice 2005 59 632-638. (doi:10.1111/j.1742-1241.2005.00518.x)
37. Fischer E, Reuschl S, Quinkler M, Rump LC, Hahner S, Bidlingmaier M & Reincke M. Assay characteristics influence the aldosterone to renin ratio as a screening tool for primary aldosteronism: results of the German Conn's Registry. Hormone and Metabolic Research 2013 45 526-531. (doi:10.1055/s-0033-1343448)
38. Bergstralh EJ & Kosanke JL. Computerized matching of cases to controls. Technical Report Number 56. The Mayo Foundation 1995. Available from http://www.mayo.edu/research/departments-divisions/department-health-sciences-research/division-biomedical-statistics-informatics/technical-reports. Accessed 14th April 2015.
39. Jin HM, Zhou DC, Gu HF, Qiao QY, Fu SK, Liu XL & Pan Y. Antioxidant N-acetylcysteine protects pancreatic b-cells against aldosterone-induced oxidative stress and apoptosis in female db/db mice and insulin-producing MIN6 cells. Endocrinology 2013 154 4068-4077. (doi:10.1210/en.2013-1115)
40. Sherajee SJ, Fujita Y, Rafiq K, Nakano D, Mori H, Masaki T, Hara T, Kohno M, Nishiyama A & Hitomi H. Aldosterone induces vascular insulin resistance by increasing insulin-like growth factor-1 receptor and hybrid receptor. Arteriosclerosis, Thrombosis, and Vascular Biology 2012 32 257-263. (doi:10.1161/ATVBAHA.111.240697)
41. Urbanet R, Pilon C, Calcagno A, Peschechera A, Hubert EL, Giacchetti G, Gomez-Sanchez C, Mulatero P, Toffanin M, Sonino N et al. Analysis of insulin sensitivity in adipose tissue of patients with primary aldosteronism. Journal of Clinical Endocrinology and Metabolism 2010 95 4037-4042. (doi:10.1210/jc.2010-0097)
42. Fischer E, Adolf C, Pallauf A, Then C, Bidlingmaier M, Beuschlein F, Seissler J & Reincke M. Aldosterone excess impairs first phase insulin secretion in primary aldosteronism. Journal of Clinical Endocrinology and Metabolism 2013 98 2513-2520. (doi:10.1210/jc.2012-3934)
43. Corry DB & Tuck ML. The effect of aldosterone on glucose metabolism. Current Hypertension Reports 2003 5 106-109. (doi:10.1007/s11906-003-0065-2)
44. Fallo F, Federspil G, Veglio F & Mulatero P. The metabolic syndrome in primary aldosteronism. Current Diabetes Reports 2008 8 42-47. (doi:10.1007/s11892-008-0009-y)
45. Helderman JH, Elahi D, Andersen DK, Raizes GS, Tobin JD, Shocken D & Andres R. Prevention of the glucose intolerance of thiazide diuretics by maintenance of body potassium. Diabetes 1983 32 106-111. (doi:10.2337/diab.32.2.106)
46. Rowe JW, Tobin JD, Rosa RM & Andres R. Effect of experimental potassium deficiency on glucose and insulin metabolism. Metabolism 1980 29 498-502. (doi:10.1016/0026-0495(80)90074-8)
47. Chatterjee R, Yeh HC, Shafi T, Selvin E, Anderson C, Pankow JS, Miller E & Brancati F. Serum and dietary potassium and risk of incident type 2 diabetes mellitus: the Atherosclerosis Risk in Communities (ARIC) study. Archives of Internal Medicine 2010 170 1745-1751. (doi:10.1001/archinternmed.2010.362)
48. Howell SL & Taylor KW. Potassium ions and the secretion of insulin by islets of Langerhans incubated in vitro. Biochemical Journal 1968 108 17-24. (doi:10.1042/bj1080017)
49. Luther JM, Luo P, Kreger MT, Brissova M, Dai C, Whitfield TT, Kim HS, Wasserman DH, Powers AC & Brown NJ. Aldosterone decreases glucose-stimulated insulin secretion in vivo in mice and in murine islets. Diabetologia 2011 54 2152-2163. (doi:10.1007/s00125-011-2158-9)
50. Ronconi V, Turchi F, Rilli S, Di Mattia D, Agostinelli L, Boscaro M & Giacchetti G. Metabolic syndrome in primary aldosteronism and essential hypertension: relationship to adiponectin gene variants. Nutrition, Metabolism, and Cardiovascular Diseases 2010 20 93-100. (doi:10.1016/j.numecd.2009.03.007)
51. Iacobellis G, Petramala L, Cotesta D, Pergolini M, Zinnamosca L, Cianci R, De Toma G, Sciomer S & Letizia C. Adipokines and cardiometabolic profile in primary hyperaldosteronism. Journal of Clinical Endocrinology and Metabolism 2010 95 2391-2398. (doi:10.1210/jc.2009-2204)
52. Somloova Z, Widimsky J Jr, Rosa J, Wichterle D, Strauch B, Petrak O, Zelinka T, Vlkova J, Masek M, Dvorakova J et al. The prevalence of metabolic syndrome and its components in two main types of primary aldosteronism. Journal of Human Hypertension 2010 24 625-630. (doi:10.1038/jhh.2010.65)